Advertisement
Advertisement
TOPIC

Biomedicine: Policy

Related Topics:
Biomedicine: Policy
Learn about China’s biomedical breakthroughs, from cutting-edge pharmaceuticals to life-saving research, driving global health innovation.
A Chinese biotech company is hoping AI technology will help to boost profits and speed up chromosome testing which is a vital part of In vitro fertilisation. Photo: Dreamstime/TNS
Banking & finance

Chinese company to use AI-powered testing to boost profits and fast-track IVF

China’s falling fertility rate sees spike in demand for assisted reproduction as biotech firm raises US$101 million from Hong Kong listing.

videocam
China’s private sector

China’s obesity drug makers take on global giants as Novo Nordisk patent expires

Banking & finance

Hong Kong attracts wave of biotech IPO filings amid AI drug research boom

Biomedicine: Companies

In a first for China, Neuracle’s brain-computer interface wins approval

China’s BCI start-ups, seen as potential rivals to Elon Musk’s Neuralink, gain momentum as regulatory support and new capital fuel growth.

A man demonstrates a robotic hand with a brain-computer interface at the China International Import Expo on November 7, 2025. Neuracle’s regulatory milestone underscores China’s accelerating push in neurotechnology. Photo: AFP
Banking & finance

China investors energise Hong Kong biotech stocks. Is foreign money missing out?

Stock Connect reshuffle reflects biotech sector’s growing role on international stage, though overseas funds remain cautious.

Insilico

Insilico Medicine advances Middle East push with UAE AI drug discovery deal

Hong Kong-listed biotech firm’s shares jump after announcing partnership to use AI tools in drug discovery in the United Arab Emirates.

Advertisement
Advertisement
Advertisement
Two Sessions 2026

China and Hong Kong should relax biotech listing rules, venture capitalist says

Foreign investors are returning to China’s healthcare sector, but IPO bottlenecks and takeover rules could deter deals, VC Nisa Leung says.

Biotechnology was explicitly included as a “strategic emerging pillar industry” in China’s government work report during the “two sessions” Photo: Shutterstock
Made in China 2025

China biotech outlicensing tops US$52 billion in first 2 months

The latest deals are Sino Biopharmaceutical’s partnership with France’s Sanofi and Antengene’s agreement with Belgium’s UCB.

Two Sessions 2026

Healthcare investors looking to ‘two sessions’ for clarity on drug pricing

Healthcare and insurance sectors will see policy fine-tuning, ‘moral support’ rather than ‘groundbreaking news’ from Beijing, analysts say.

China’s private sector

Biomedicine | China challenges US in new drugs after industry transformation

Drug makers in China are performing cutting-edge research and licensing products to global giants after a 10-year government push supercharged the industry.

China challenges US in new drugs after industry transformation
Made in China 2025

Chinese biotechs strike a record US$136 billion in out-licensing deals in 2025

Chinese drug makers signed 157 out-licensing deals with global pharmaceutical firms last year versus 94 a year earlier.

Last year, China approved 76 innovative drugs, including 47 chemical drugs and 23 biologics. Photo: Shutterstock
Made in China 2025

China’s new drug insurance: lifeline for patients or squeeze on big firms?

New insurance formulary trims costs of Alzheimer’s and cancer therapies and marks a small win for global novel drug makers.

China economy

Opinion | How China engineered the rapid rise of its drug innovation industry

A market once dominated by generics is now an AI-powered pharmaceutical hub drawing billion-dollar investments from the likes of Pfizer and GSK.

videocam
Hong Kong healthcare and hospitals

Editorial | Hospital fee reform must balance social fairness with budgetary needs

While standard X-ray services at public hospitals will remain free, the pricing overhaul must be watched closely to avoid unintended harm.

People at the Shroff Office of Queen Elizabeth Hospital in Jordan on March 25. Photo: Jelly Tse
Biomedicine: Industry Trends

China’s clinical trial capacity matches US, attracts more global pharma firms

Growth of innovative clinical trials suggests that Chinese biotech firms’ pipeline of novel drug candidates is expanding, analysts say.

China had 2,694 new clinical trials in 2024, up 13 per cent from a year earlier. Photo: Shutterstock
New medical drugs

6 of the best: the billion-dollar biotechs putting China on the map

China’s biotech renaissance is gathering pace as home-grown innovators strike billion-dollar licensing deals with global giants.

China’s private sector

‘Quantity to quality’: what China’s next 5-year plan means for foreign investors

Beijing has pledged to open up even more to foreign investment. But some officials are becoming more selective about the projects they want.

videocam
Advertisement
Advertisement
Advertisement
Biomedicine: Industry Trends

China’s drug developers stretch to become a global force

Although a start-up’s recent triumph is seen as a ‘DeepSeek moment’, domestic players still trail world-beating pharma firms, experts say.

10
Illustration: Henry Wong
Baidu

Baidu-backed drug discovery start-up Biomap challenges Google’s AlphaFold

Biomap expects to double its revenue this year, co-founder and CEO Wei Liu says.

US-China tech war

Chinese 3D biomolecule imaging start-up aims for IPO in 2027

Shuimu BioSciences is the first Chinese company to develop its own cryo-electron microscopy machine, a vital tool in drug discovery.

China manufacturing

China closes biotech gap with US as new drugs, pipelines top 30% of global total

Beijing has ramped up support for the bioeconomy with a five-year plan aimed at making the country a global leader by 2035.

Operating microscope and the flag of China. Photo: Shutterstock
Biomedicine: Companies

China’s biomedicine sector takes off

China’s novel drug industry is experiencing a meteoric rise, fuelled by the increased development of new medicines and the prospect of many patents expiring.

China to cash in on biomedicines ‘patent cliff’
Hong Kong economy

Opinion | How Hong Kong can lead in patient-focused ethical AI healthcare

AI can improve disease detection, surgery accuracy and data management but healthcare professionals can do a lot of good that AI cannot.

videocam
Biomedicine: Companies

Hong Kong firms eye Chinese medicine opportunities on the mainland: HKTDC

Hong Kong Trade Development Council says streamlined procedures opened a more convenient channel for companies to expand into the mainland.

China manufacturing

China approving innovative drugs at record pace, shifting momentum from West

‘If we’re not careful, every drug could be made in China,’ warned former head of US Food and Drug Administration in May.

videocam
8
Employees package medicine at a pharmaceutical company in China’s Shaanxi province. Photo: Xinhua
Biomedicine: Companies

China’s plan to boost drug coverage no ‘magic wand’: analysts

Drug companies will be eager to have their products approved, but insurers will struggle to offer attractive coverage, analysts say.

A worker at Shijiazhuang Yiling Pharmaceutical works on a production line in Shijiazhuang, Hebei province, on November 4, 2021. Photo: Xinhua
Biomedicine: Companies

CUHK start-ups eye silver economy’s need for ‘wearable robotics’

Start-ups seek to enter the growing markets for elderly care and rehabilitation by selling their ‘wearable robotics’ technologies.

China's economic recovery

Explainer | Why is Xi turning to the ocean for China’s growth – and who benefits?

Beijing eyes ocean-driven growth, as Chinese leader pledges more support for offshore sectors like wind power, shipping and marine biotech.

Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement